
JG-98
CAS No. 1456551-16-8
JG-98 ( JG98 )
产品货号. M11970 CAS No. 1456551-16-8
JG-98 是一种变构 Hsp70 抑制剂,对乳腺癌细胞系 MDA-MB-231 和 MCF-7 的活性和稳定性比 MKT-077 高 3 倍以上(EC50 分别为 0.4 uM 和 0.7 uM)。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥1199 | 有现货 |
![]() ![]() |
5MG | ¥2130 | 有现货 |
![]() ![]() |
10MG | ¥3426 | 有现货 |
![]() ![]() |
25MG | ¥5565 | 有现货 |
![]() ![]() |
50MG | ¥7938 | 有现货 |
![]() ![]() |
100MG | ¥10773 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称JG-98
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述JG-98 是一种变构 Hsp70 抑制剂,对乳腺癌细胞系 MDA-MB-231 和 MCF-7 的活性和稳定性比 MKT-077 高 3 倍以上(EC50 分别为 0.4 uM 和 0.7 uM)。
-
产品描述JG-98 is an allosteric Hsp70 inhibitor, displays >3-fold more active, greater stability than MKT-077 against the breast cancer cell lines MDA-MB-231 and MCF-7 (EC50 of 0.4 uM and 0.7 uM, respectively); strongly affects autophagic flux, increases p62 oligomerization and reduces p62 monomer; destabilizes FoxM1 and relieved suppression of downstream effectors, including p21 and p27.
-
体外实验JG-98 (30 nM-30 μM; 72 hours) has antiproliferative activity across a range of cell lines with the EC50s between ~0.3 and 4 μM.JG-98 (10 μM; 48 hours) activates apoptotic mediators (cleavage of caspase-3 and PARP) in MDA-MB-231 cells.JG-98 destabilizes FoxM1 and relieves suppression of downstream effectors, including p21 and p27. Cell Proliferation Assay Cell Line:MCF-7, MDA-MB-231, A375, MeWo, HeLa, HT-29, SKOV3, Jurkat, mouse embryonic fibroblasts (MEF), MM1.R, INA6, RPMI-8226, JJN-3, U266, NCI-H929, L363, MM1.S, KMS11, LP-1, AMO-1, OPM1, OPM2 cells Concentration:30 nM-30 μM Incubation Time:72 hours Result:Active against all of the lines tested, and the EC50s were variable (between ~0.3 μM and 4 μM). Normal MEFs and OPM1 and OPM2 were relatively less sensitive.Western Blot Analysis Cell Line:MDA-MB-231 cells Concentration:10 μM Incubation Time:48 hours Result:Incudes apoptotic mediators cleavage of caspase 3 and PARP.
-
体内实验JG-98 (3 mg/kg; i.p.; on days 0, 2, and 4) suppresses tumor growth in xenograft models bearing MCF7 and HeLa cells. Animal Model:6-week-old NCR mice (xenografts of MCF7 and HeLa cells) Dosage:3 mg/kg Administration:Intraperitoneal injection; on days 0, 2, and 4 Result:Limited tumor growth, but somewhat less effectively.
-
同义词JG98
-
通路Cytoskeleton/Cell Adhesion Molecules
-
靶点HSP
-
受体HSP70
-
研究领域——
-
适应症——
化学信息
-
CAS Number1456551-16-8
-
分子量534.532
-
分子式C24H21Cl2N3OS3
-
纯度>98% (HPLC)
-
溶解度DMSO: Soluble ( < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESCCN1C(=CC2=[N+](C=CS2)CC3=CC=CC=C3)SC(=C4N(C5=C(S4)C=C(C=C5)Cl)C)C1=O.[Cl-]
-
化学全称Thiazolium,2-[(Z)-[(5E)-5-(6-chloro-3-methyl-2(3H)-benzothiazolylidene)-3-ethyl-4-oxo-2-thiazolidinylidene]methyl]-3-(phenylmethyl)-,chloride (1:1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Li X. et al. ACS Med Chem Lett. 2013 Nov 14;4(11).
2. Li X, et al. Mol Cancer Ther. 2015 Mar;14(3):642-8.